UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

(Rule 13d-102)

 

Under the Securities Exchange Act of 1934

(Amendment No. 2)

 

IMMATICS N.V.

(Name of Issuer)

 

Ordinary shares, nominal value €0.01 per share

(Title of Class of Securities)

 

N44445109

(CUSIP Number)

 

December 31, 2022

(Date of Event Which Requires Filing of This Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  Rule 13d-1(b)

 

  Rule 13d-1(c)

 

  Rule 13d-1(d)

 

  * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

 

 

 

 

 

 

CUSIP NO. N44445109   13 G   Page 2 of 15 Pages

 

1.   

Name of Reporting Persons

 

dievini Hopp BioTech holding GmbH & Co. KG

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)   (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

17,202,356 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

17,202,356 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

17,202,356 ordinary shares (2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

Percent of Class Represented by Amount in Row (9)

 

26.2(3)

12.  

Type of Reporting Person (See Instructions)

 

OO

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 3 of 15 Pages

 

1.   

Name of Reporting Persons

 

DH-LT-Investments GmbH

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)   (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With:

  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

726,282 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

726,282 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

726,282 ordinary shares (2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

Percent of Class Represented by Amount in Row (9)

        

1.1%(3)

12.  

Type of Reporting Person (See Instructions)

 

OO

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents 726,282 shares of record held by DH-LT Investments for which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 4 of 15 Pages

 

1.   

Name of Reporting Persons

 

DH-Capital GmbH & Co. KG

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)   (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person

With:

  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

17,202,356 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

17,202,356 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

17,202,356 ordinary shares common shares (2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 

 

11.  

Percent of Class Represented by Amount in Row (9)

 

26.2%(3)

12.  

Type of Reporting Person (See Instructions)

 

OO

 

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 5 of 15 Pages

 

1.   

Name of Reporting Persons

 

OH Beteiligungen GmbH & Co. KG

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)   (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

17,202,356 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

17,202,356 ordinary shares(2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

17,202,356 ordinary shares(2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 

 

11.  

Percent of Class Represented by Amount in Row (9)

 

26.2%(3)

12.  

Type of Reporting Person (See Instructions)

 

OO

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 6 of 15 Pages

 

1.   

Name of Reporting Persons

 

Dietmar Hopp

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)  ☐ (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

17,202,356 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

17,202,356 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

17,202,356 ordinary shares(2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 

 

11.  

Percent of Class Represented by Amount in Row (9)

 

26.2%(3)

12.  

Type of Reporting Person (See Instructions)

 

IN

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 7 of 15 Pages

 

1.   

Name of Reporting Persons

 

Oliver Hopp

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)   (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

17,202,356 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

17,202,356 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

17,202,356 ordinary shares(2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

Percent of Class Represented by Amount in Row (9)

 

26.2%(3)

12.  

Type of Reporting Person (See Instructions)

 

IN

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents 14,901,384 shares held of record by dievini, 726,282 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 8 of 15 Pages

 

1.  

Name of Reporting Persons

 

Daniel Hopp

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)  ☐        (b)  ☐ (1)

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

17,202,356 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

17,202,356 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

17,202,356 ordinary shares (2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

Percent of Class Represented by Amount in Row (9)

 

26.2%(3)

12.  

Type of Reporting Person (See Instructions)

 

IN

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents 14,901,384 shares held of record by dievini, 726.,82 shares of record held by DH-LT Investments, 329,521 shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum, 627,524 shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, and 617,645 shares held of record by 4H invest GmbH a company wholly owned and controlled by Dr. Hettich, over all of which dievini has shared voting and dispositive power,.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 9 of 15 Pages

 

1.  

Name of Reporting Persons

 

Prof. Dr. Friedrich von Bohlen und Halbach

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)   (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

627,524 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

627,524 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

627,524 ordinary shares (2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) 

 

11.  

Percent of Class Represented by Amount in Row (9)

 

1.0%(5)

12.  

Type of Reporting Person (See Instructions)

 

IN

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents shares held by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen, for which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 10 of 15 Pages

 

1.  

Name of Reporting Persons

 

Prof. Dr. Christof Hettich

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)   (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
With:
  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

617,645 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

617,645 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

617,645 ordinary shares (2)

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

Percent of Class Represented by Amount in Row (9)

 

0.9(3)

12.  

Type of Reporting Person (See Instructions)

 

IN

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents shares held by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich, for which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 11 of 15 Pages

 

1.  

Name of Reporting Persons

 

Dr. Mathias Hothum

2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a)          (b)   (1) 

3.  

SEC USE ONLY

 

4.  

Citizenship or Place of Organization

 

Germany

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person

With:

  5.   

Sole Voting Power

 

0 ordinary shares

  6.  

Shared Voting Power

 

329,521 ordinary shares (2)

  7.  

Sole Dispositive Power

 

0 ordinary shares

  8.  

Shared Dispositive Power

 

329,521 ordinary shares (2)

9.  

Aggregate Amount Beneficially Owned by Each Reporting Person

 

329,521 (2) ordinary shares

10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

 

11.  

Percent of Class Represented by Amount in Row (9)

 

0.5(3)

12.  

Type of Reporting Person (See Instructions)

 

IN

 

(1)This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH& Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

 

(2)Represents shares held by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum for which dievini has shared voting and dispositive power.

 

(3)This percentage is calculated based on 65,634,347 shares of the Issuer’s common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on November 17, 2022.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 12 of 15 Pages

 

Introductory Note: This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG (“dievini”), DH-LT-Investments, GmbH (“DH-LT-Investments”), DH-Capital GmbH & Co. KG (“DH-Capital”), OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”), Prof. Dr. Christof Hettich (“Dr. Hettich”), Dr. Mathias Hothum (“Dr. Hothum” and together with dievini, DH-LT Investments, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the “Reporting Persons”) in respect of ordinary shares of Immatics N.V.

 

Item 1(a) Name of Issuer:

 

Immatics N.V.

 

Item 1(b) Address of Issuer’s principal executive offices:

 

Paul-Ehrlich-Straße 15

72076 Tübingen, Germany

 

Items 2(a) Name of Reporting Persons filing:

 

dievini Hopp BioTech holding GmbH & Co. KG (“dievini”)

DH-LT-Investments GmbH (“DH-LT-Investments”)

DH-Capital GmbH & Co. KG (“DH-Capital”)

OH Beteiligungen GmbH & Co. KG (“OH Beteiligungen”)

Dietmar Hopp

Oliver Hopp

Daniel Hopp

Prof. Dr. Friedrich von Bohlen und Halbach (“Dr. von Bohlen”)

Prof. Dr. Christof Hettich (“Dr. Hettich”)

Dr. Mathias Hothum (“Dr. Hothum”)

 

Item 2(b) Address or principal business office or, if none, residence:

 

The address of the principal business office of dievini, DH-LT Investments, and Dietmar Hopp is c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany.

 

The address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Heidelberger Straße 43, 69168 Wiesloch, Germany.

 

The address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.

 

The address of the principal business office of Daniel Hopp is Johann-Jakob-Astor-Straße 57, 69190 Walldorf, Germany.

 

The address of Dr. Hettich is Silcherstraße 6, 68723 Schwetzingen, Germany.

 

The address of Dr Hothum is Bürgermeister-Willinger-Straße 3, 69190 Walldorf, Germany.

 

The address of Dr von Bohlen is Neuenheimer Landstraße 4, 69120 Heidelberg, Germany.

 

Item 2(c) Citizenship:

 

Name   Citizenship or Place of Organization
Dievini   Germany
DH-Capital   Germany
OH Beteiligungen   Germany
Dietmar Hopp   Germany
Oliver Hopp   Germany
Daniel Hopp   Germany
Dr. von Bohlen   Germany
Dr. Hettich   Germany
Dr. Hothum   Germany
DH-LT Investments   Germany

 

 

 

 

CUSIP NO. N44445109   13 G   Page 13 of 15 Pages

 

Item 2(d) Title of class of securities:

 

Ordinary shares, nominal value €0.01 per share.

 

Item 2(e) CUSIP No.:

 

N44445109

 

Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

 

Not applicable.

 

Item 4 Ownership

 

The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  

 

DH-Capital and OH Beteiligungen are collectively the holders of 100% of the limited partner interest in dievini and therefore, control the voting and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp, Oliver Hopp and Daniel Hopp are the ultimate controlling persons of dievini, DH-Capital and OH Beteiligungen, and control the voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the shares held by dievini by virtue of their status as controlling persons of dievini.

 

Item 5 Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:  

 

Item 6 Ownership of More than Five Percent on Behalf of Another Person

 

Not applicable.

 

Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

 

Not applicable.

 

Item 8 Identification and Classification of Members of the Group

 

Not applicable.

 

Item 9 Notice of Dissolution of Group

 

Not applicable.

 

Item 10 Certifications

 

Not applicable.

 

 

 

 

CUSIP NO. N44445109   13 G   Page 14 of 15 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 10, 2023

 

  DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG
     
  By: dievini Verwaltungs GmbH
    its General Partner
     
  By: /s/ Dr. Marc Hauser
    Name: Dr. Marc Hauser
    Title: Attorney-in-fact
   
  DH-CAPITAL GMBH & CO. KG
     
  By: DH Verwaltungs GmbH
    its General Partner
     
  By: /s/ Dr. Marc Hauser
    Name: Dr. Marc Hauser
    Title: Attorney-in-fact
   
  OH BETEILIGUNGEN GMBH & CO. KG
     
  By: OH Verwaltungs GmbH
    its General Partner
     
  By: /s/ Dr. Marc Hauser
    Name:  Dr. Marc Hauser
    Title: Attorney-in-fact

 

  /s/ Dr. Marc Hauser as attorney-in-fact
  DIETMAR HOPP
   
  /s/ Dr. Marc Hauser as attorney-in-fact
  OLIVER HOPP
   
  /s/ Dr. Marc Hauser as attorney-in-fact
  DANIEL HOPP
   
  /s/ Dr. Marc Hauser as attorney-in-fact
  FRIEDRICH VON BOHLEN UND HALBACH
   
  /s/ Dr. Marc Hauser as attorney-in-fact
  CHRISTOF HETTICH
   
  /s/ Dr. Marc Hauser as attorney-in-fact
  MATHIAS HOTHUM

 

  DH-LT INVESTMENTS GMBH
     
  By: /s/ Dr. Marc Hauser
  Name:  Dr. Marc Hauser
  Title: Attorney-in-fact

 

 

 

 

CUSIP NO. N44445109   13 G   Page 15 of 15 Pages

 

Exhibit(s):

 

1 – Power of Attorney: Incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons on February 12, 2021 with respect to the common shares of the Issuer.
   
2 – Joint Filing Statement: Incorporated by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on February 12, 2021 with respect to the common shares of the Issuer.